Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze

Neuroscience Letters

Volumn 495, Issue 1, 2011, Pages 63-66

  Sela, Vânia Ramos ^a   Biesdorf, Carla ^a   Ramos, Diego Henrique ^a   Zangrossi, Hélio ^b   Graeff, Frederico Guilherme ^b   Audi, Elisabeth Aparecida ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adrenergic antagonist; 5 HT1A receptor; Antidepressant; Dorsal periaqueductal gray; Panic disorder

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PINDOLOL; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DORSAL PERIAQUEDUCTAL GRAY MATTER; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; LATENT PERIOD; MALE; MAZE TEST; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DRUG SYNERGISM; ESCAPE REACTION; MALE; MAZE LEARNING; PANIC; PAROXETINE; PERIAQUEDUCTAL GRAY; PINDOLOL; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 79954986890     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.03.040     Document Type: Article

References (38)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994, 51:248-251.
2. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action?. Trends Pharmacol. Sci. 2001, 22:224-228.
3. Artigas F., Adell A., Celada P. Pindolol augmentation of antidepressant response. Curr. Drug Targets 2006, 7:139-147.
4. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a doubleblind, placebo-controlled trial. Am. J. Psychiatry 1997, 154:37-43.
5. Blier P., de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999, 21:91-98.
6. Cremers T.I, Wiersma L.J., Bosker F.J., Den Boer J.A., Westerink B.H., Wikstrom H.V. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?. Biol. Psychiatry 2001, 50:13-21.
7. De Bortoli V.C., Nogueira R.L., Zangrossi H. Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology (Berl) 2006, 183:422-428.
8. Del-Ben C.M., Graeff F.G. Panic disorder: is the PAG involved?. Neural Plast. 2009, 2009:1-9.
9. Graeff F.G., Zangrossi H. Animal models of anxiety disorders. Biol. Psychiatry 2002, 879-893. Wiley, Chichester, UK. H. D'Haenen, J.A. den Boer, P. Willner (Eds.).
10. Haddjeri N., Blier P. Effect of sustained (±)pindolol administration on serotonin neurotransmission in rats. J. Psychiatry Neurosci. 2000, 25:378-388.
11. Hirschmann S., Dannon P.N., Iancu I., Dolberg O.T., Zohar J., Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2000, 20:556-559.
12. Hjorth S., Bengtsson H.J., Milano S. Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or betaadrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur. J. Pharmacol. 1996, 316:43-47.
13. Kim T.S., Pae C.U., Yoon S.J., Bahk W.M., Jun T.Y., Rhee W.I., Chae J.H. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin. Neurosci. 2006, 60:347-351.
14. Martinez D., Hwang D.R., Mawlawi O., Slifstein M., Kent J., Simpson N., Parsey R.V., Hashimoto T., Huang Y., Shinn A., van Heertum R., Abi-Dargham A., Caltabiano S., Malizia A., Cowley H., John Mann J., Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5HT1A receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 2001, 24:209-229.
15. Miguez J.M., Paz-Valinas L., Miguez I., Aldegunde M. Somatodendritic action of pindolol to attenuate the paroxetine-induced decrease in serotonin release from the rat ventral hippocampus: a microdialysis study. Naunyn. Schmiedebergs Arch. Pharmacol. 2002, 365:378-387.
16. Nogueira R.L., Graeff F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol. Biochem. Behav. 1995, 52:1-6.
17. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Academic Press, San Diego. 5rd ed.
18. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997, 349:1594-1597.
19. Pobbe R.L.H, Zangrossi H. 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus. Psychopharmacology (Berl.) 2005, 183:314-321.
20. Rickels K., Zaninelli R., McCafferty J., Bellew R., Iyengar M., Sherhan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry 2003, 160:749-756.
21. Romero L., Bel N., Artigas F., de Montigny C., Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HTIA receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996, 15:349-360.
22. Schutz M.T., de Aguiar J.C., Graeff F.G. Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. Psychopharmacology (Berl) 1985, 85:340-345.
23. Sela V.R., Roncon C.M., Zangrossi H., Graeff F.G., Audi E.A. Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze. Life Sci. 2010, 87:445-450.
24. Segrave R., Nathan P.J. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum. Psychopharmacol. 2005, 20:163-174.
25. Sheehan D.V., Burnham D.B., Iyengar M.K., Perera P., Paxil C.R. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry 2005, 66:34-40.
26. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51:215-235.
27. Teixeira R.C., Zangrossi H., Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 2000, 65:571-576.
28. Thase M.E., Rush A.J. Treatment-resistant depression. Psychopharmacology: The Fourth Generation of Progress 1995, 1081-1097. Raven Press, New York, NY. F.E. Bloom, D.J. Kupfer (Eds.).
29. Trivedi M.H., Pigotti T.A., Perera P., Dillingham K.E., Carfagno M.L., Pitts C.D. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J. Clin. Psychiatry 2004, 65:1356-1364.
30. Van Vliet I.M., Westenberg H.G.M., den Boer J.A. Pindolol does not augment the panicolytic effects of fluvoxamine in panic disorders patients. Eur. Neuropsychopharmacol. 1998, 8:S257-S258.
31. Viana M.B., Graeff F.G., Löschmann P.A. Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal gray. Pharmacol. Biochem. Behav. 1997, 58:167-172.
32. Zanoveli J.M., Nogueira R.L., Zangrossi H. Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. Eur. J. Pharmacol. 2003, 473:153-161.
33. Zanoveli J.M., Nogueira R.L., Zangrossi H. Chronic imipramine treatment sensitizes 5-HT1A and 5-HT2A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav. Pharmacol. 2005, 16:543-552.
34. Zanoveli J.M., Nogueira R.L., Zangrossi H. Enhanced reactivity of 5-HT1A receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: evidence from the elevated T-maze. Neuropharmacology 2007, 52:1188-1195.
35. Zanoveli J.M., Pobbe R.L.H., de Bortoli V.C., Carvalho M.C., Brandão M.L., Zangrossi H. Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine. Int. J. Neuropsychopharmacol. 2010, 13:1079-1088.
36. Ziegenbein M., Steiger S., Murck H. Treatment with the presynaptic 5-HT1A-antagonist pindolol in patients with panic disorder. Biol. Psychiatry 2000, 47:S81.
37. Ziegenbein M., Steiger S., Murck H. Pindolol in panic disorder. Eur. Psychiatry 2002, 17:163.
38. Zohar J., Dannon P.N., Sasson Y., Hirschmann S., Iancu I., Grunhaus L.J. Pindolol augmentation in treatment-resistant panic disorder and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 1998, 8:S99.